About Us

Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine


The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.

Latest News


TLX101 for Brain Cancer IPAX-1 Study Update

Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...


NDA Clinical Briefing Package Submitted to the US FDA

Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...


Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...


Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...